CCL2 and diabetic kidney disease: Although we evaluated urinary MCP‐1 concentration as a candidate biomarker of the severity of diabetic nephropathy,12 monitoring of pharmacological inhibition of CCR2 may be required to further investigate the efficacy of PG in future definitive trials.